SPONSOR
InxMed (Shanghai) Co., Ltd.
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 2, Phase 3
Conditions studied: Small Cell Lung Cancer Extensive StageSolid Tumor CancerPDACNon-Small Cell Lung Cancer
InxMed (Shanghai) Co., Ltd. is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Small Cell Lung Cancer Extensive Stage, Solid Tumor Cancer, PDAC, Non-Small Cell Lung Cancer.
The trial portfolio spans Phase 1, Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — InxMed (Shanghai) Co., Ltd.
How many clinical trials has InxMed (Shanghai) Co., Ltd. sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by InxMed (Shanghai) Co., Ltd., of which 3 are actively recruiting participants. These trials cover conditions including Small Cell Lung Cancer Extensive Stage, Solid Tumor Cancer, PDAC. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does InxMed (Shanghai) Co., Ltd. research focus on?
InxMed (Shanghai) Co., Ltd. clinical trials span Small Cell Lung Cancer Extensive Stage, Solid Tumor Cancer, PDAC, Non-Small Cell Lung Cancer. The research pipeline includes Phase 1, Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a InxMed (Shanghai) Co., Ltd. clinical trial?
To participate in a InxMed (Shanghai) Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all InxMed (Shanghai) Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by InxMed (Shanghai) Co., Ltd.
NCT06030258 Phase 1, Phase 2
Recruiting
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Small Cell Lung Cancer Extensive Stage
NCT07441174 Phase 1, Phase 2
Recruiting
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
Solid Tumor Cancer
NCT07174908 Phase 3
Recruiting
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Non-Small Cell Lung Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology